Stocks · News reference

Immuron Sees Prelim FY2026 Sales $5.462M

Jul 16, 2026, 10:25 AMBenzinga Newsdesk

Immuron (NASDAQ:IMRN) sees Prelim FY2026 sales of $5.462 million.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncJul 16, 2026, 10:00 AMNa
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Immuron Limited announced FY26 unaudited sales of AUD$7.7 million, up 6% year-over-year, driven by growth in Australia (+10%) and the USA (+7% AUD, +13% USD) for its Travelan® product. Australia's growth was attributed to increased digital marketing, same-store growth, and new retail placements, while US growth benefited from improved Amazon presence and social media initiatives. Canada showed exceptional Q4 growth of 427% on prior comparative period following pipeline fill in FY25, though full-year Canada sales declined 55% due to timing of initial stocking.
Read original at globenewswire-inc
IMRN
Globenewswire IncJul 6, 2026, 10:00 AMImmuron Limited
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for IMM-529, its investigational polyclonal antibody treatment for Clostridioides difficile infection (CDI). The company has FDA approval for the IND application and is preparing for Phase 2 clinical trials in Australia. Based on market assessments, IMM-529 could generate projected annual revenues of US$400M if efficacious, with potential partnership deals ranging from US$1-50M upfront plus significant milestone payments and royalties.
Read original at globenewswire-inc
IMRN